Author Interviews, Cancer Research, JAMA, Weight Research / 02.11.2025
GLP-1RA Use May Reduce Risk of Developing Several Obesity-Related Cancers
MedicalResearch.com Interview with:
Jiang Bian, PhD
Associate Dean of Data Science
Walther and Regenstrief Professor of Cancer Informatics
Professor of Biostatistics & Health Data Science
Adjunct Professor, Biomedical Engineering and Informatics
Chief Data Scientist, Regenstrief Institute
Chief Data ScientistCustomize & Schedule Social Media Posts
Indiana University Health
Serena Jingchuan Guo, MD PhD
Assistant Professor
Department of Pharmaceutical Outcomes and Policy
University of Florida College of Pharmacy
Hao Dai, PhD
Postdoctoral Fellow
Department of Biostatistics & Health Data Science
Indiana University School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Obesity and type 2 diabetes are both known to increase the risk of several cancers. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become very popular for both glycemic control and weight loss, but their long-term effects on cancer risk are still unclear. Using a large real-world dataset, we emulated a target trial comparing more than 43,000 GLP-1RA users to matched non-users.
We found that GLP-1RA use was associated with a significantly lower overall cancer risk.
(more…)